TrialAnnals of hematology2023

Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.

Peter J P Croucher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.